All Articles by Author:

Danielle Corrigan

Nanoparticle-Induced Chemoresistance: The Emerging Modulatory Effects of Engineered Nanomaterials on Human Intestinal Cancer Cell Redox Metabolic Adaptation

[Nanoscale] Investigators screened several representative food-borne comparator engineered nanomaterials and reported that human colon cancer cells could insidiously exploit ZnO nanoparticle-induced adaptive response to acquire resistance against several chemotherapeutic drugs.

NudCD1 as a Prognostic Marker in Colorectal Cancer and Its Role in the Upregulation of Cellular Spindle Assembly Checkpoint Genes and LIS1 Pathways

[BMC Cancer] Scientists investigated the role of NudCD1 in spindle assembly checkpoint regulation and in the prognosis of colorectal cancer.

Repurposing Metformin as a Potential Treatment for Inflammatory Bowel Disease: Evidence from Cell to the Clinic

[International Immunopharmacology] Scientists discuss the beneficial effects of metformin on IBD using the results of in vitro, in vivo, and clinical studies.

Transcriptional Switch of Hepatocytes Initiates Macrophage Recruitment and T-Cell Suppression in Endotoxemia

[Journal of Hepatology] The spatial and temporal changes in hepatocytes and non-parenchymal cell types were validated by multiplex immunofluorescence staining, bulk transcriptomic sequencing, or flow cytometry.

TIPE1 Promotes Liver Regeneration by Enhancing Ros-FoxO1 Axis Mediated Autophagy

[FEBS Journal] Hepatic Tipe1 deficiency decreased the level of reactive oxygen species in hepatocytes, which led to the inhibition of FoxO1 acetylation and LC3I to LC3II conversion, and p62 accumulation.

Knockdown of Hepatocyte Perilipin-3 Mitigates Hepatic Steatosis and Steatohepatitis Caused by Hepatocyte CGI-58 Deletion in Mice

[Journal of Molecular Biology] Scientists test whether the deletion of a major lipid droplet protein alleviates fatty liver pathogenesis caused by alpha/beta hydrolase domain containing 5 deficiency in hepatocytes.


Truqap Plus Faslodex Approved in the EU for Patients with Advanced ER-Positive Breast Cancer

[AstraZeneca] AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the European Union (EU) for the treatment of adult patients with ER-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.

Breast Cancer Exploits Neural Signaling Pathways for Bone-to-Meninges Metastasis

[Science] Scientists applied a combination of intravital and ex vivo three-dimensional confocal microscopy, micro–computed tomography, and histologic analyses to mouse models of bone-metastatic breast cancer and leptomeninges (LM) metastasis,. They demonstrated that breast cancer cells could traffic to the LM from the bone marrow through abluminal emissary vein migration.

RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis

[Cancer Research] Investigators employed a CRISPR/Cas9 screening strategy that revealed RUVBL1 and RUVBL2 as putative targets. Loss of RUVBL1/2 preferentially impaired the growth of YTHDF1-high colorectal cancer (CRC) cells, patient-derived primary CRC organoids, and subcutaneous xenografts.